QGEN vs. RPRX: Qiagen vs. Royalty Pharma Stock Comparison

Company Profile

Qiagen (QGEN) and Royalty Pharma (RPRX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but QGEN is classified in Life Sciences Tools & Services while RPRX is classified in Pharmaceuticals.

Qiagen (QGEN) has more than two decades of public-market history since June 28, 1996, whereas Royalty Pharma (RPRX) listed on June 16, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Qiagen (QGEN) at 10.81% and Royalty Pharma (RPRX) at 12.09% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Qiagen (QGEN) at 18.20% and Royalty Pharma (RPRX) at 25.70% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Qiagen (QGEN) at 27.75% and Royalty Pharma (RPRX) at 81.32% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Qiagen (QGEN) at 5.65% and Royalty Pharma (RPRX) at 5.06% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Qiagen (QGEN) at 409.76% clears its industry range for EPS growth, a much stronger earnings trajectory than Royalty Pharma (RPRX) at 23.09%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Qiagen (QGEN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Royalty Pharma (RPRX) at 1.29 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for RPRX.

Qiagen (QGEN) at 0.47 carries an industry-typical debt-to-equity mix, while Royalty Pharma (RPRX) at 0.88 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Both Qiagen (QGEN) at 0.71% and Royalty Pharma (RPRX) at 1.37% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Qiagen (QGEN) at 18.21% and Royalty Pharma (RPRX) at 60.46% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Qiagen (QGEN) at 27.21 is near its industry’s usual P/E ratio, while Royalty Pharma (RPRX) at 43.99 sits in the richer quartile — RPRX needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Qiagen (QGEN) at 4.91 and Royalty Pharma (RPRX) at 14.79 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

On P/B ratio, both Qiagen (QGEN) at 2.99 and Royalty Pharma (RPRX) at 4.39 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics